Certis Oncology is a precision oncology and translational science company. We provide clinically relevant, predictive data that informs treatment decisions, empowers cancer patients, and reduces drug development risk. At Certis, we don’t challenge market leaders or competitors. We challenge resistance to change—a mindset willing to accept the status quo or “good enough.”
Our mission is to connect every patient to the right therapy for their cancer—the first time, every time. In the future we envision, cancer is powerless against our science.
ABOUT OUR METHODS
Our approach is rooted in a technology rapidly gaining prominence in basic research: orthotopic patient derived xenograft (O-PDX) models. By surgically engrafting a small tissue specimen of your patient’s tumor into the anatomically correct place in immunocompromised mice, we create mouse “avatars” of the patient’s cancer. The resulting O-PDX models enable simultaneous, in vivo functional assays of multiple therapeutic options in the laboratory.
A large and expanding body of scientific literature substantiates that tumors in O-PDX models closely replicate genetic and histological characteristics of their human counterparts, making them highly predictive tools for evaluating drug response. Because disease progression is accelerated in mice, O-PDX models are especially useful in predicting resistance and response to second-line therapy–before these events are observed in the patient.
To learn more, please visit certisoncology.com